SCHEMBL1385895

SCHEMBL1385895

CCOc1cccc(NC(=O)c2cc(C)n(-c3ccccc3C(F)(F)F)c2C)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 4/20 0.57
KCNK9 Q9NPC2 4/20 0.57
TAAR1 Q96RJ0 1/20 0.54
NOTUM Q6P988 1/20 0.48
RXFP1 Q9HBX9 1/20 0.46
F2R P25116 1/20 0.46
MAPT P10636 1/20 0.46
TOP2A P11388 1/20 0.46
CNR1 P21554 1/20 0.44
CNR2 P34972 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 2/20 0.44
NR1H4 Q96RI1 1/20 0.43
FADS1 O60427 1/20 0.43
NPC1 O15118 1/20 0.43
POLB P06746 1/20 0.43
CASP3 P42574 1/20 0.43
RAB9A P51151 1/20 0.43
SENP8 Q96LD8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1380193 0.90 RAB9A (0.51) KCNK3KCNK9RXFP1MAPTCNR1
SCHEMBL1379728 0.90 PDK1 (0.52) KCNK3KCNK9TAAR1CNR1CNR2
SCHEMBL1385014 0.90 SGMS2 (0.48) KCNK3KCNK9TAAR1RXFP1F2R
SCHEMBL1380190 0.89 RAB9A (0.53) KCNK3KCNK9RXFP1MAPTCNR1
SCHEMBL1380127 0.89 KCNK3 (0.46) KCNK3KCNK9TAAR1RXFP1F2R
SCHEMBL1380760 0.88 NPY5R (0.51) KCNK3KCNK9MAPTTOP2ACNR1
SCHEMBL1378243 0.88 CNR1 (0.48) KCNK3KCNK9RXFP1F2RMAPT
SCHEMBL1381483 0.88 KCNK3 (0.47) KCNK3KCNK9RXFP1F2RMAPT
SCHEMBL1378540 0.88 KCNK3 (0.46) KCNK3KCNK9TAAR1RXFP1F2R
SCHEMBL1380773 0.88 NR1H4 (0.49) KCNK3KCNK9TAAR1RXFP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4703649-B2 2011-06-15 JP claimed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 US disclosed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 US disclosed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 US disclosed
US-20110144128-A1 Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands EXELIXIS, INC. (US) 2011-06-16 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 KCNK3 3073/4885KCNK9 3876/4885TAAR1 204/4885
US-20110144128-A1 Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands NCOA1, NCOA2, NCOA3 KCNK3 3491/4885KCNK9 3695/4885TAAR1 632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.